Symbols

AORT

Artivion·NYSE

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AORT

Artivion, Inc.

A leading cardiac and vascular surgery company focused on aortic disease

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

07/15/1997

Exchange

New York Stock Exchange

Full-time Employees

1,800

Fiscal Year Ends

12-31

Website

www.artivion.com

Security Type

Common stock

Office address

1655 Roberts Boulevard N.W., Kennesaw, GA 30144

Business

Introduction

Artivion, Inc., was incorporated in Florida in 1984 and changed its state of incorporation from Florida to Delaware on January 1, 2022. The company is a leader in the manufacture, processing and distribution of medical devices and implantable human tissue for cardiac and vascular surgery in patients with aortic disease. The company has four main product lines: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implanted cardiac and vascular human tissue.

Company Financials

EPS

AORT has released its 2025 Q4 earnings. EPS was reported at 0.17, versus the expected 0.06, beating expectations. The chart below visualizes how AORT has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AORT has released its 2025 Q4 earnings report, with revenue of 115.99M, reflecting a YoY change of 19.20%, and net profit of 2.43M, showing a YoY change of 114.72%. The Sankey diagram below clearly presents AORT's revenue sources and cost distribution.